Mirati Therapeutics Inc. (MRTX)
NASDAQ: MRTX
· Real-Time Price · USD
58.70
-0.10 (-0.17%)
At close: Jan 22, 2024, 10:00 PM
Mirati Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 16.4M | 13.69M | 7.17M | 934K | 5.43M | 5.36M | 709K | 299K | 71.79M | n/a | n/a |
Cost of Revenue | 1.69M | 1.28M | 817K | 141.84M | 131.08M | 128.34M | 130.98M | 153.84M | 116.11M | 134.57M | 104.07M |
Gross Profit | 13.86M | 12.41M | 6.35M | -140.9M | -125.64M | -122.98M | -130.27M | -153.54M | -44.32M | -134.57M | -104.07M |
Operating Income | -172.05M | -187.27M | -193.82M | -211.72M | -186.44M | -177.21M | -184.22M | -197.07M | -79.5M | -164.19M | -132.42M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -161.9M | -176.91M | -184.59M | -202.22M | -173.31M | -176.44M | -188.39M | -199.62M | -76.75M | -166.43M | -135.68M |
Net Income | -161.9M | -176.91M | -184.59M | -202.47M | -173.56M | -176.44M | -188.39M | -200.15M | -80.05M | -166.43M | -135.68M |
Selling & General & Admin | 72M | 75.49M | 73.49M | 70.82M | 60.8M | 54.23M | 53.95M | 43.53M | 35.18M | 29.61M | 28.35M |
Research & Development | 114.77M | 124.19M | 126.68M | 141.24M | 131.08M | 128.34M | 130.98M | 153.84M | 116.11M | 134.57M | 104.07M |
Other Expenses | 259K | 258K | 259K | 600K | 13.14M | 760K | -4.17M | -2.54M | 2.74M | -2.24M | -3.26M |
Operating Expenses | 187.03M | 199.68M | 200.17M | 212.06M | 191.87M | 182.57M | 184.93M | 197.37M | 151.29M | 164.19M | 132.42M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | 4.17M | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | -98.16M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 188.45M | 200.96M | 200.99M | 212.66M | 191.87M | 182.57M | 184.93M | 197.37M | 151.29M | 164.19M | 132.42M |
Income Tax Expense | -1.11M | n/a | -9.24M | 254K | 254K | 149K | 4.17M | 139K | 3.3M | -145K | n/a |
Shares Outstanding (Basic) | 64.99M | 58.23M | 58.03M | 57.67M | 56.22M | 55.55M | 55.41M | 53.62M | 51.66M | 51.47M | 50.78M |
Shares Outstanding (Diluted) | 64.99M | 58.23M | 58.03M | 57.67M | 56.22M | 55.55M | 55.47M | 53.62M | 51.66M | 51.47M | 50.78M |
EPS (Basic) | -2.49 | -3.04 | -3.02 | -3.51 | -3.09 | -3.18 | -3.48 | -3.73 | -1.55 | -3.23 | -2.67 |
EPS (Diluted) | -2.49 | -3.04 | -3.02 | -3.51 | -3.09 | -3.18 | -3.47 | -3.73 | -1.55 | -3.23 | -2.67 |
EBITDA | -170.94M | -186.16M | -192.75M | -210.83M | -185.73M | -176.51M | -183.59M | -197.07M | -78.98M | -163.78M | -132.13M |
EBIT | -172.05M | -187.27M | -187.67M | -208.41M | -186.44M | -177.21M | -184.22M | -197.07M | -79.5M | -164.19M | -132.42M |
Depreciation & Amortization | 1.11M | 1.11M | 1.07M | 891K | 716K | 693K | 629K | 562K | 514K | 411K | 294K |